SCHEMBL24601353

SCHEMBL24601353

CC(C)(C)c1ccc(C(=O)Nc2ccc3[nH]c(C(O)O)cc3c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.52
MAOB P27338 2/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HDAC3 O15379 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50
KCNK9 Q9NPC2 1/20 0.50
TRPV1 Q8NER1 6/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
NR1H4 Q96RI1 2/20 0.47
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
ATM Q13315 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
KCNK3 O14649 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22718631 0.81 MAOA (0.56) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL22718661 0.81 HDAC6 (0.60) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL22718557 0.80 PLD2 (0.56) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL13483892 0.77 NPC1 (0.71) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL22718571 0.77 MAOA (0.51) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL22718539 0.76 MMP13 (0.68) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL5973321 0.76 MAPT (0.67) MEN1KMT2AHDAC3HDAC6HDAC11
SCHEMBL6418643 0.76 MAPT (0.75) MEN1KMT2AHDAC3HDAC6HDAC11
SCHEMBL22718599 0.75 HDAC6 (0.50) MAOAMAOBMEN1KMT2AHDAC3
SCHEMBL22718595 0.75 HDAC6 (0.50) MAOAMAOBMEN1KMT2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213052-A1 INHIBITORS OF RNA-BINDING PROTEINS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEROF THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2022-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213052-A1 INHIBITORS OF RNA-BINDING PROTEINS, COMPOSITIONS THEREOF, AND THERAPEUTIC USES THEROF HNRNPF, RBM3, RBM15 MAOA 4560/4885MAOB 3990/4885MEN1 2899/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.